Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes

Clinical Pharmacokinetics

Volumn 58, Issue 6, 2019, Pages 781-791

  Granhall, Charlotte ^a   Donsmark, Morten ^a   Blicher, Thalia M ^a   Golor, Georg ^b   Søndergaard, Flemming L ^a   Thomsen, Mette ^a   Bækdal, Tine A ^a  

^a NOVO NORDISK A S   (Denmark)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; SALCAPROZIC ACID; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1;

ADULT; AORTIC ANEURYSM; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DECREASED APPETITE; DIET; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELIMINATION RATE CONSTANT; EXERCISE; FASTING; GASTROINTESTINAL DISEASE; HUMAN; HYPOGLYCEMIA; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TABLET; UPPER ABDOMINAL PAIN; ADOLESCENT; BLOOD; DOSE RESPONSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; YOUNG ADULT;

EID: 85058850333     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-018-0728-4     Document Type: Article

References (12)

1. Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4:1443–67.
2. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11:905–10.
3. Ismail R, Csóka I. Novel strategies in the oral delivery of antidiabetic peptide drugs—insulin, GLP 1 and its analogs. Eur J Pharm Biopharm. 2017;115:257–67.
4. Tan X, Cao X, Zhou M, Zou P, Hu J. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2017;26:1083–9.
5. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10:eaar7047.
6. Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella-Lawson F, FitzGerald GA. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation. 1998;98:1610–5.
7. Bittner B, McIntyre C, Tian H, et al. Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). Pharmazie. 2012;67:233–41.
8. Castelli MC, Wong DF, Friedman K, Riley MG. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. Clin Ther. 2011;33:934–45.
9. American Diabetes Association. Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycaemia. Diabetes Care. 2005;28:1245–9.
10. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460–70.
11. Bækdal TA, Borregaard J, Donsmark M, Breitschaft A, Søndergaard FL. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide [abstract]. Diabetes. 2017;66(Suppl 1):A315.
12. Carlsson Petri KC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Semaglutide s.c. once-weekly in type 2 diabetes: a population pharmacokinetic analysis. Diabetes Ther. 2018;9:1533–47.